{"id":58472,"date":"2024-02-27T18:37:42","date_gmt":"2024-02-27T18:37:42","guid":{"rendered":"https:\/\/medsname.com\/cozartan-h\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"cozartan-h","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/cozartan-h\/","title":{"rendered":"Cozartan-H"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Cozartan-H?<\/h3>\n<p style=\"margin:0;\"><strong>Cozartan-H<\/strong> er en <strong>50\/12.5 mg fixed-dose tablet<\/strong> of losartan 50 mg and <strong>hydrochlorothiazid<\/strong> fra Torrent Pharmaceuticals \u2014 en <strong>trin-2 antihypertensiv kombination<\/strong> til patienter, hvis blodtryk ikke er kontrolleret med <a href=\"https:\/\/medsbase.com\/da\/losar\/\">Losar<\/a> (losartan monotherapy) alone. Adding a thiazide diuretic typically yields an additional <strong>5-10 mmHg systolisk blodtryksfald<\/strong> ud over ARB-monoterapi. De to komponenter virker gennem <strong>komplement\u00e6re mekanismer<\/strong> (ARB'en blokerer angiotensin-II-receptoren; HCTZ reducerer natrium og inducerer mild volumenkontraktion) og har <strong>gensidigt afbalancerede bivirkningsprofiler<\/strong> \u2014 HCTZ s\u00e6nker kalium, mens ARB'en har tendens til at \u00f8ge det, s\u00e5 kombinationen er mindre tilb\u00f8jelig til at for\u00e5rsage enten hypokali\u00e6mi eller hyperkali\u00e6mi end hvert enkelt l\u00e6gemiddel ved tilsvarende doser. Typisk dosering: \u00e9n tablet \u00e9n gang dagligt. <strong>Absolut kontraindikeret under graviditet<\/strong> (begge komponenter), <strong>anuri eller sv\u00e6r nyreinsufficiens (eGFR &lt;30)<\/strong>, <strong>thiazid (sulfonamid) overf\u00f8lsomhed<\/strong>, og <strong>symptomatisk hyponatri\u00e6mi<\/strong>. Overv\u00e5g kalium, natrium, urat og kreatinin under behandling.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede <a href=\"https:\/\/medsbase.com\/da\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er d\u00e6kket af vores <a href=\"https:\/\/medsbase.com\/da\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Cozartan-H?<\/h2>\n<p>Cozartan-H is an oral fixed-dose combination tablet supplying <strong>losartan 50 mg<\/strong> og <strong>hydrochlorothiazid (HCTZ)<\/strong> in a single pill, made by Torrent Pharmaceuticals and supplied in 30-180 tablets. It combines two first-line antihypertensive drug classes in a ratio chosen for most patients who have progressed beyond ARB monotherapy. Losartan is the <strong>first ARB approved for clinical use<\/strong> (DuPont Merck 1995; originator brand Cozaar). Half-life ~2 hours for the parent drug and 6-9 hours for the active metabolite E-3174 (generated by CYP2C9 and CYP3A4).<\/p>\n<p>Hydrochlorothiazide (HCTZ) er en thiazid-diuretikum introduceret i 1959 (MSD som HydroDiuril). Det forbliver et af de mest ordinerede antihypertensive l\u00e6gemidler globalt og er <strong>den fjerde retningslinje-anbefalede f\u00f8rstevalgsklasse<\/strong> for hypertension sammen med ARB'er, ACE-h\u00e6mmere og calciumkanalblokkere.<\/p>\n<h2 class=\"wp-block-heading\">Hvorfor kombinere en ARB med en thiazid?<\/h2>\n<p>Hypertension kontrolleres sj\u00e6ldent med et enkelt l\u00e6gemiddel i m\u00e5ldosis. Studier som ALLHAT, ACCOMPLISH og ASCOT fastslog, at <strong>de fleste hypertensive patienter har brug for to eller tre l\u00e6gemidler fra forskellige klasser<\/strong> for at n\u00e5 retningslinjernes blodtryksm\u00e5l (&lt;140\/90 for de fleste voksne, &lt;130\/80 for diabetikere og CKD). ARB + thiazid er en af de tre evidensbaserede tokombinationer (de to andre er ARB + CCB og CCB + thiazid).<\/p>\n<p>The two components of Cozartan-H complement each other on <strong>fire farmakologiske akser<\/strong>:<\/p>\n<ul>\n<li><strong>Komplement\u00e6re blodtrykss\u00e6nkende mekanismer.<\/strong> ARB'en blokerer vasokonstriktion og aldosteron-drevet natriumretention; HCTZ reducerer total kropsnatrium og producerer mild volumenkontraktion. Additivt blodtryksfald (typisk 5-10 mmHg systolisk ud over ARB-monoterapi).<\/li>\n<li><strong>RAAS modregulering.<\/strong> Thiazider aktiverer renin-angiotensin-aldosteron-systemet som en kompensatorisk reaktion p\u00e5 natriumtab \u2014 dette d\u00e6mper normalt deres effekt. Blokering af AT<sub>1<\/sub> receptoren med en ARB <strong>forhindrer denne kompensatoriske aktivering<\/strong> og frig\u00f8r den fulde antihypertensive effekt af thiazid.<\/li>\n<li><strong>Kaliumbalance.<\/strong> HCTZ mister kalium gennem den distale tubulus (klassisk hypok\u00e6mifare). ARB'er \u00f8ger kalium ved at blokere aldosteron-medieret kaliumudskillelse. Kombinationen opretholder derfor et mere fysiologisk kaliumniveau end hvert middel alene \u2014 klinisk synligt som f\u00e6rre hypok\u00e6mieepisoder under sambehandling med loop-diuretika og f\u00e6rre klinisk signifikante hyperk\u00e6mier end ARB-monoterapi.<\/li>\n<li><strong>Volumaktiveringsmodregulering.<\/strong> ARB-induceret vasodilatation kan udl\u00f8se natriumretention hos saltf\u00f8lsomme patienter (en klassisk \u00e5rsag til \u201ctabt\u201d blodtryksrespons efter uger med behandling). Den natriuretiske effekt fra HCTZ afbryder denne retentionscyklus.<\/li>\n<\/ul>\n<p>Losartan is <strong>uniquely uricosuric among ARBs<\/strong> &mdash; it lowers serum uric acid by inhibiting the URAT1 transporter in the proximal tubule. This is clinically important in this combination, because <strong>HCTZ raises serum uric acid<\/strong> by competing for the same excretory pathway. The losartan-HCTZ combination is therefore <strong>the preferred ARB+thiazide pairing for patients with gout, hyperuricaemia, or who are sensitive to thiazide-induced urate rises<\/strong>.<\/p>\n<p><strong>Evidens for ARB+HCTZ:<\/strong> Det <strong>LIFE-studiet (2002)<\/strong> used losartan with HCTZ add-on as its active arm, demonstrating a 13% reduction in stroke, cardiovascular death, and myocardial infarction versus atenolol-based therapy in hypertensive patients with left-ventricular hypertrophy. RENAAL (2001) established renoprotection in type 2 diabetic nephropathy.<\/p>\n<h2 class=\"wp-block-heading\">Dosering &amp; Titrering<\/h2>\n<p><strong>Standarddosis:<\/strong> one 50\/12.5 mg tablet once daily, typically in the morning (HCTZ causes a mild diuresis; evening dosing can disrupt sleep with night-time urination).<\/p>\n<p><strong>When to start Cozartan-H:<\/strong><\/p>\n<ul>\n<li>BP not controlled on losartan 50 mg monotherapy after 4-6 weeks at target dose<\/li>\n<li>Stadie 2 hypertention (\u2265160\/100) som en startkombination \u2014 det er at foretr\u00e6kke at starte to l\u00e6gemidler fra forskellige klasser frem for titrering med et enkelt middel ved sv\u00e6r hypertention if\u00f8lge AHA\/ACC-retningslinjerne<\/li>\n<li>Opgradering fra en ACE-h\u00e6mmer\/HCTZ-kombination, n\u00e5r ACE-h\u00e6mmeren har for\u00e5rsaget hoste<\/li>\n<\/ul>\n<p><strong>Titration:<\/strong> hvis blodtrykket forbliver ukontrolleret efter 4-6 uger p\u00e5 den indledende FDC, kan en fastdosis tablet med h\u00f8jere styrke erstattes (de fleste producenter tilbyder 50\/12,5, 100\/12,5, 80\/12,5, 160\/12,5 og 160\/25 kombinationer af det relevante ARB med HCTZ). Alternativt kan en tredje klasse tilf\u00f8jes \u2014 typisk en <a href=\"https:\/\/medsbase.com\/da\/amlode\/\">calciumkanalblokker (amlodipin)<\/a>.<\/p>\n<p><strong>Overv\u00e5gningsplan:<\/strong><\/p>\n<ul>\n<li><strong>Baseline:<\/strong> urea, elektrolytter (natrium, kalium), kreatinin, eGFR, serumurat, fastende glukose, lipider. Hjemme- eller klinikblodtryk.<\/li>\n<li><strong>1-2 uger efter start eller dosis\u00e6ndring:<\/strong> gentag U&amp;E. Forvent en lille stigning i kreatinin (op til 30% er acceptabel), et lille fald i natrium (1-3 mmol), en lille stigning i urat (delvis modvirket i produkter, der indeholder losartan). Kalium er typisk stabilt i normalt omr\u00e5de.<\/li>\n<li><strong>4-6 uger:<\/strong> Blodtryksgennemgang for at vurdere respons; gentag U&amp;E, hvis der er nogen elektrolytforstyrrelse p\u00e5 et tidligere tidspunkt.<\/li>\n<li><strong>L\u00f8bende:<\/strong> \u00e5rlig U&amp;E, urat, glukose og lipider, n\u00e5r det er stabilt. Hjemmeblodtryk to gange om ugen.<\/li>\n<li><strong>Stop og unders\u00f8g:<\/strong> symptomatisk hyponatri\u00e6mi (forvirring, kvalme, lethargi; serum Na &lt;130), kalium 5,5, kreatininstigning &gt;30%, ny eller forv\u00e6rret gigt, overf\u00f8lsomhedsudsl\u00e6t.<\/li>\n<\/ul>\n<p><strong>Oph\u00f8r:<\/strong> ingen abstinenssyndrom, men pludselig stop for\u00e5rsager gradvis blodtryksrebound over flere dage. Trappes ned ved at erstatte med en kombination med lavere styrke eller vende tilbage til ARB-monoterapi under blodtryksmonitorering.<\/p>\n<h2 class=\"wp-block-heading\">Bivirkninger<\/h2>\n<p>Bivirkninger overlapper dem for begge komponentl\u00e6gemidler. Kombinationen er normalt <strong>bedre tolereret<\/strong> end enten komponent ved maksimal monoterapidosis, fordi doserne i fast kombination er lavere end toppunktet for monoterapidoser.<\/p>\n<p><strong>Almindelige (&gt;1% af brugerne):<\/strong><\/p>\n<ul>\n<li>Svimmelhed, postural hypotoni (normalt mild; mere almindelig i de f\u00f8rste 1-2 uger)<\/li>\n<li>Mild diurese \u2014 \u00f8get vandladning de f\u00f8rste par dage, som typisk aftager, n\u00e5r v\u00e6skebalancen stabiliseres<\/li>\n<li>Mild hyponatri\u00e6mi eller hypokali\u00e6mi hos modtagelige patienter<\/li>\n<li>Forventet lille stigning i kreatinin (op til 30%)<\/li>\n<li>Tr\u00e6thed, hovedpine, nasofaryngitis<\/li>\n<li>Hyperurik\u00e6mi (typisk asymptomatisk; sj\u00e6ldent udl\u00f8ser gigt \u2014 mindre sandsynligt ved losartan-indeholdende kombinationer)<\/li>\n<li>Fotosensitivitetsudsl\u00e6t (thiazid-relateret)<\/li>\n<\/ul>\n<p><strong>Ikke almindelige, men klinisk vigtige:<\/strong><\/p>\n<ul>\n<li><strong>Alvorlig hyponatri\u00e6mi<\/strong> \u2014 risikoen er h\u00f8jest hos \u00e6ldre kvinder med lav-salt di\u00e6t, hjerteinsufficiens eller tendens til SIADH. Unders\u00f8g enhver ny forvirring, kvalme eller fald med serum-natrium.<\/li>\n<li><strong>Udl\u00f8sning af akut gigt<\/strong> \u2014 mere sandsynligt ved valsartan+HCTZ eller telmisartan+HCTZ end losartan+HCTZ. Skift til losartan-baseret kombination ved gentagen forekomst.<\/li>\n<li><strong>Metabolisk forstyrrelse<\/strong> \u2014 forv\u00e6rret glucosetolerance (5-8 mg\/dL gennemsnitlig stigning i fastende-glukose), beskeden stigning i LDL og triglycerider. Telmisartan modvirker dette delvist via PPAR-\u03b3-aktivitet.<\/li>\n<li><strong>Angio\u00f8dem<\/strong> \u2014 lavere rate end ACE-h\u00e6mmere, men muligt. Stop \u00f8jeblikkeligt; erstat med en ikke-RAAS-agent.<\/li>\n<li><strong>Akut nyreskade ved volumenmangel eller bilateral nyrearteriestenose<\/strong><\/li>\n<li><strong>Pankreatitis<\/strong> \u2014 sj\u00e6lden bivirkning fra thiazid-klassen; stop \u00f8jeblikkeligt ved enhver \u00f8vre mavesmerte med stigning i lipase.<\/li>\n<li><strong>Akut myopi og vinkelblokglaukom<\/strong> \u2014 sj\u00e6lden sulfonamid-klasse reaktion, typisk inden for timer til dage efter start p\u00e5 nyt sulfonamid. Stop og s\u00f8g akut oftalmologisk vurdering ved pludselig smertefuldt \u00f8je eller syns\u00e6ndring.<\/li>\n<li><strong>Trombocytopeni, leukopeni<\/strong> \u2014 sj\u00e6ldne reaktioner fra thiazid-klassen<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikationer<\/h2>\n<ul>\n<li><strong>Graviditet \u2014 ABSOLUT kontraindikation i alle trimestre.<\/strong> Begge komponenter: ARB'er for\u00e5rsager fetal nyreagenesi, oligohydramnion, pulmonal hypoplasi; HCTZ passerer placentaen og kan for\u00e5rsage fetal eller neonatal gulsot og trombocytopeni. Skift til <a href=\"https:\/\/medsbase.com\/da\/labebet\/\">labetalol<\/a>, methyldopa eller nifedipin f\u00f8r undfangelse.<\/li>\n<li><strong>Anuri eller sv\u00e6r nyreinsufficiens<\/strong> (eGFR &lt;30 mL\/min\/1,73 m\u00b2) \u2014 HCTZ mister effekt ved lav GFR, og ARB&#039;en medf\u00f8rer risiko for akut nyreskade<sup>2<\/sup>) \u2014 HCTZ loses efficacy at low GFR and the ARB risks AKI<\/li>\n<li><strong>Thiazid- eller sulfonamidoverf\u00f8lsomhed<\/strong><\/li>\n<li><strong>Symptomatisk hyponatri\u00e6mi (Na &lt;130)<\/strong> ved baseline \u2014 vil forv\u00e6rres<\/li>\n<li><strong>Symptomatisk hypokali\u00e6mi (K &lt;3.0)<\/strong> eller hypomagnesi\u00e6mi ved baseline \u2014 korriger f\u00f8rst<\/li>\n<li><strong>Hyperkalc\u00e6mi<\/strong> \u2014 HCTZ \u00f8ger calcium ved at reducere urinudskillelsen<\/li>\n<li><strong>Sv\u00e6r leversvigt<\/strong> (Child-Pugh C) \u2014 risiko for at udl\u00f8se hepatisk encefalopati via elektrolytskift<\/li>\n<li><strong>Tidligere angio\u00f8dem med enhver ACE-h\u00e6mmer eller ARB<\/strong> (inden for 4 uger; langsigtet forsigtig brug er ofte acceptabel under specialistvejledning)<\/li>\n<li><strong>Bilateral nyrearteriestenose<\/strong><\/li>\n<li><strong>Samtidig sacubitril\/valsartan (Entresto)<\/strong> \u2014 36 timers udvaskning p\u00e5kr\u00e6vet<\/li>\n<li><strong>Samtidig aliskiren ved diabetes eller CKD<\/strong> (ALTITUDE-skade)<\/li>\n<li><strong>Samtidig ACE-h\u00e6mmer<\/strong> \u2014 ONTARGET-skade uden gavn<\/li>\n<\/ul>\n<p><strong>Amning:<\/strong> HCTZ udskilles i m\u00e6lk og kan h\u00e6mme laktation ved h\u00f8jere doser; generelt undg\u00e5s i de f\u00f8rste uger efter f\u00f8dslen af en for tidlig f\u00f8dt baby. Alternative antihypertensiva (propranolol, nifedipin) foretr\u00e6kkes, n\u00e5r det er muligt.<\/p>\n<h2 class=\"wp-block-heading\">L\u00e6gemiddelinteraktioner<\/h2>\n<ul>\n<li><strong>Lithium \u2014 KRITISK INTERAKTION.<\/strong> Thiazider reducerer lithiums renale clearance og kan udl\u00f8se lithiumforgiftning. Undg\u00e5 kombinationen hvis muligt; hvis det er uundg\u00e5eligt, overv\u00e5g lithium-niveauer ugentligt den f\u00f8rste m\u00e5ned og reducer lithium-dosis med 25-50%.<\/li>\n<li><strong>NSAID'er \u2014 risiko for \u201ctriple whammy\u201d.<\/strong> ARB + diuretikum + NSAID = h\u00f8j risiko for akut nyreskade (AKI) ved hypovol\u00e6mi eller samtidig sygdom (infektion, dehydrering). Begr\u00e6ns NSAID'er til kortvarig lejlighedsvis brug; paracetamol foretr\u00e6kkes.<\/li>\n<li><strong>Kaliumtilskud, kaliumsparende diuretika (spironolakton, eplerenon, amilorid)<\/strong> \u2014 hyperkalaemi p\u00e5 trods af HCTZ-induceret kaliumtab. Overv\u00e5g n\u00f8je.<\/li>\n<li><strong>Digoxin<\/strong> \u2014 HCTZ-induceret hypokalaemi forst\u00e6rker digoxinforgiftning. Overv\u00e5g kalium- og digoxinniveauer.<\/li>\n<li><strong>Orale kortikosteroider<\/strong> \u2014 additiv hypokalaemi og v\u00e6skeophobning (delvist modvirker thiazid-effekten)<\/li>\n<li><strong>Amphotericin B, stimulerende aff\u00f8ringsmidler<\/strong> \u2014 additiv risiko for hypokalaemi<\/li>\n<li><strong>Orale antidiabetika, insulin<\/strong> \u2014 thiazider forv\u00e6rrer glucosetolerance; diabetisk HbA1c kan stige 0,1-0,3%. Mindre bekymring med telmisartan+HCTZ end andre ARB+HCTZ-kombinationer (telmisartans PPAR-\u03b3-aktivitet modvirker delvist thiazideffekten).<\/li>\n<li><strong>Cholestyramin \/ colestipol<\/strong> \u2014 reducerer HCTZ-absorption med 40-85%. Adskil dosering med 4 timer.<\/li>\n<li><strong>Alkohol<\/strong> \u2014 additiv postural hypotoni, is\u00e6r ved dosetitration<\/li>\n<li><strong>Fluconazole, rifampicin<\/strong> &mdash; affect CYP2C9\/3A4 activation of losartan to E-3174 metabolite; may alter BP effect<\/li>\n<li><strong>Andre ACE-h\u00e6mmere, andre ARB'er, aliskiren<\/strong> \u2014 kombiner ikke<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Cozartan-H vs ARB Monotherapy &mdash; When to Step Up<\/h2>\n<p>Cozartan-H is a <strong>trin-2-pr\u00e6parat<\/strong>, ikke et f\u00f8rstevalgsmedicin. Ved nyopst\u00e5et hypertension uden komplikationer:<\/p>\n<ol>\n<li><strong>Start<\/strong> med <a href=\"https:\/\/medsbase.com\/da\/losar\/\">Losar<\/a> (losartan monotherapy) (or a calcium-channel blocker; or an ACE inhibitor if no ACEi-cough history)<\/li>\n<li><strong>Titr\u00e9r<\/strong> til m\u00e5ldosis over 4-6 uger<\/li>\n<li><strong>Hvis blodtrykket stadig er ukontrolleret<\/strong>, move to Cozartan-H (ARB + thiazide) <strong>eller<\/strong> tilf\u00f8j en CCB (ARB + CCB). Begge er evidensbaserede kombinationer.<\/li>\n<li><strong>Hvis blodtrykket stadig er ukontrolleret efter 4-6 uger p\u00e5 kombination<\/strong>, skift til en trippelkombination: ARB + CCB + thiazid<\/li>\n<li><strong>Ud over trippelkombination<\/strong>, tilf\u00f8j spironolakton (PATHWAY-2-studiet viser evidens for resistent hypertension) eller henvis til specialistunders\u00f8gelse (nyrearteriestenose, prim\u00e6r hyperaldosteronisme, f\u00f8okromocytom)<\/li>\n<\/ol>\n<p>Patients with uncomplicated stage 2 hypertension (&ge;160\/100) may reasonably start directly on Cozartan-H &mdash; current AHA\/ACC guidelines prefer early two-drug initiation for severe hypertension over single-drug titration.<\/p>\n<h2 class=\"wp-block-heading\">Opbevaring<\/h2>\n<p>Store Cozartan-H below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Ofte stillede sp\u00f8rgsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">Is Cozartan-H a first-line blood-pressure drug?<\/h3>\n<p>Nej \u2014 fastdosis ARB\/thiazid-kombinationer er <strong>trin-2-midler<\/strong>. Standardtilgangen er at starte med ARB-monoterapi (<a href=\"https:\/\/medsbase.com\/da\/losar\/\">Losar<\/a> (losartan monotherapy)), titrate to target dose, and move to Cozartan-H only if BP is not controlled after 4-6 weeks. An exception: stage 2 hypertension (&ge;160\/100) can reasonably start on two-drug therapy directly per AHA\/ACC guidelines.<\/p>\n<h3 class=\"wp-block-heading\">When should I take Cozartan-H &mdash; morning or evening?<\/h3>\n<p><strong>Morgen<\/strong> er standarden. HCTZ-komponenten er et diuretikum \u2014 det \u00f8ger urinproduktionen i 2-4 timer efter dosering. Aftendosering kan forstyrre s\u00f8vnen med natlig vandladning. Nogle patienter med nattetidshypertension (ikke-dippere, kronisk nyresygdom) kan blive r\u00e5det til at skifte til aftendosering for at m\u00e5lrette det tidlige morgenblodtryk; dr\u00f8ft med din l\u00e6ge.<\/p>\n<h3 class=\"wp-block-heading\">Hvor meget ekstra blodtryksfald kan jeg forvente i forhold til <a href=\"https:\/\/medsbase.com\/da\/losar\/\">Losar<\/a> (losartan monotherapy) alone?<\/h3>\n<p>Cirka <strong>5-10 mmHg yderligere systolisk og 3-6 mmHg yderligere diastolisk<\/strong> on average, measured 4-6 weeks after starting Cozartan-H. The additive effect comes from blocking the compensatory RAAS activation that normally blunts thiazide monotherapy; that blockade unlocks HCTZ&rsquo;s full effect.<\/p>\n<h3 class=\"wp-block-heading\">My potassium is normal on an ARB &mdash; will it drop on Cozartan-H?<\/h3>\n<p>Normalt forbliver det inden for det normale omr\u00e5de. Thiazid-induceret kaliumtab er <strong>delvist modvirket af ARB\u2019s tendens til at h\u00e6ve kalium<\/strong>. A small number of patients do develop hypokalaemia &mdash; baseline and 1-2 week follow-up U&amp;E is routine. If potassium drops below 3.5, add a potassium-sparing strategy (eplerenone, a potassium-rich diet, or occasionally potassium supplementation) rather than stopping Cozartan-H.<\/p>\n<h3 class=\"wp-block-heading\">Will Cozartan-H raise my uric acid or trigger gout?<\/h3>\n<p>Losartan uniquely <strong>s\u00e6nker<\/strong> serum uric acid by inhibiting URAT1 in the proximal tubule, which <strong>partially offsets<\/strong> HCTZ&rsquo;s urate-raising effect. Losartan + HCTZ is the <strong>preferred ARB+thiazide combination for patients with gout or hyperuricaemia<\/strong>. New-onset gout on Cozartan-H is uncommon but possible in high-risk patients (CKD, male, alcohol, obesity).<\/p>\n<h3 class=\"wp-block-heading\">I have type 2 diabetes &mdash; is Cozartan-H safe?<\/h3>\n<p>Ja, men v\u00e6r opm\u00e6rksom p\u00e5 at <strong>thiazider forv\u00e6rrer i beskeden grad glucosetolerancen<\/strong> (average fasting-glucose rise 5-8 mg\/dL, HbA1c rise 0.1-0.3%). The BP benefit outweighs this effect in most diabetics, and tighter BP control reduces diabetic kidney and eye complications more than the glucose rise increases them. Monitor HbA1c annually. If diabetic control worsens on Cozartan-H, ask about switching to <a href=\"https:\/\/medsbase.com\/da\/telma-h\/\">Telma H<\/a> (telmisartan + HCTZ), som har delvis metabolsk-beskyttende aktivitet.<\/p>\n<h3 class=\"wp-block-heading\">Can I take ibuprofen with Cozartan-H?<\/h3>\n<p>Lejlighedsvis kortvarig brug er normalt fint. <strong>Kronisk daglig brug af NSAID'er<\/strong> (ibuprofen, diclofenac, naproxen) er risikabelt ved enhver ARB + diuretikum kombination \u2014 den \u201ctriple whammy\u201d (ARB + diuretikum + NSAID) kan udl\u00f8se akut nyreskade ved dehydrering, infektion eller kirurgi. Ved kroniske smerter b\u00f8r paracetamol anvendes; ved inflammation b\u00f8r alternativer diskuteres med din l\u00e6ge.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Cozartan-H in pregnancy?<\/h3>\n<p><strong>Nej \u2014 absolut kontraindiceret.<\/strong> Begge komponenter er teratogene: ARB'en for\u00e5rsager fetal nyreagenes og oligohydramnion; HCTZ passerer placentaen og kan for\u00e5rsage fetal eller neonatal gulsot og trombocytopeni. Kvinder i den fertile alder b\u00f8r anvende p\u00e5lidelig pr\u00e6vention. For dem, der planl\u00e6gger graviditet, b\u00f8r der skiftes til <a href=\"https:\/\/medsbase.com\/da\/labebet\/\">labetalol<\/a>, methyldopa eller nifedipin <strong>f\u00f8r undfangelse<\/strong>.<\/p>\n<h3 class=\"wp-block-heading\">Will I need to urinate more at night on Cozartan-H?<\/h3>\n<p>Normalt ikke, hvis du tager tabletten om morgenen. Den diuretiske effekt topper 2-4 timer efter indtagelse og er for det meste aftaget om aftenen. Patienter, der skifter til aftenindtagelse, oplever ofte nokturi; ved at skifte tilbage til morgenindtagelse forsvinder dette inden for 1-3 dage.<\/p>\n<h3 class=\"wp-block-heading\">Hvad hvis jeg glemmer en dosis?<\/h3>\n<p>Tag det, s\u00e5 snart du husker det, medmindre det er inden for f\u00e5 timer af din n\u00e6ste dosis \u2013 i s\u00e5 fald spring den overskydende dosis over og forts\u00e6t din normale dosisplan. Tag ikke en dobbeltdosis. En enkelt overskydende dosis p\u00e5virker ikke blodtrykskontrollen v\u00e6sentligt. Hvis du har glemt mere end 2 dage, vil dit blodtryk begynde at stige igen; genoptag din s\u00e6dvanlige dosis (der er ikke behov for at \u00f8ge doseringen).<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Cozartan-H online?<\/h3>\n<p>You can buy Cozartan-H (50\/12.5 mg losartan + HCTZ, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Relaterede antihypertensiva p\u00e5 MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/aquazide\/\">Aquazide \u2014 Hydrochlorothiazid<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/coversyl\/\">Coversyl &mdash; Perindopril (ACEi alternative)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/diovan-160\/\">Diovan 160 \u2014 Valsartan 160 mg (monoterapi)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/olmezest-am\/\">Olmezest AM \u2014 Olmesartan + Amlodipin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/ramcor\/\">Ramcor \u2014 Ramipril (ACE-h\u00e6mmer alternativ)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/valzaar-h\/\">Valzaar H \u2014 Valsartan + HCTZ<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/high-blood-pressure-medication\/\"><strong>Se alle h\u00f8jtryksmedicin<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medicinsk ansvarsfraskrivelse.<\/strong> Denne side er kun til informationsform\u00e5l og erstatter ikke l\u00e6gefaglig r\u00e5dgivning fra en kvalificeret sundhedsfaglig person. Hypertension, hjerteinsufficiens og arytmier kr\u00e6ver diagnose, overv\u00e5gning og individuel dosering af en l\u00e6ge \u2014 brug altid beta-blokkere under l\u00e6gelig vejledning.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterede alternativer<\/h3>\n<p>Andre produkter inden for <strong>Kroniske tilstande<\/strong> som kunder ogs\u00e5 ser:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/betnesol-tab\/\">Betnesol-tablet<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/valent\/\">Valent<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/coversyl\/\">Coversyl<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/app-up\/\">App-Up<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/foracort-inhaler\/\">Foracort Inhaler<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Cozartan-H is Torrent&#8217;s fixed-dose losartan 50 mg + HCTZ 12.5 mg tablets \u2014 second-line combination for patients whose blood pressure is not controlled on losartan alone. The losartan component is uniquely uricosuric, offsetting HCTZ&#8217;s urate-raising effect, making this combination preferred in patients with hypertension plus gout or hyperuricaemia. Once-daily morning dosing.<\/p>","protected":false},"featured_media":58473,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3342,3260,3356],"product_tag":[4500,3401,3384],"class_list":{"0":"post-58472","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-general-health","9":"product_cat-heart-blood-pressure","10":"product_cat-high-blood-pressure-medication","11":"product_tag-cozartan-h","12":"product_tag-hydrochlorothiazide","13":"product_tag-losartan","15":"first","16":"instock","17":"shipping-taxable","18":"purchasable","19":"product-type-variable","20":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product\/58472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/comments?post=58472"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media\/58473"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media?parent=58472"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_brand?post=58472"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat?post=58472"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_tag?post=58472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}